Breast Cancer Risk Associated With CHEK2 Mutations

Suzanne M. Mahon, RN, DNSc, AOCN®, APNG

Most efforts to identify individuals who have a hereditary predisposition for developing breast cancer had focused on the BRCA1 and BRCA2 genes. Less common susceptibility genes also are associated with increased risk for developing breast cancer, but until recently have often gone undetected. With the advent of next generation sequencing (NGS), many families with suspected hereditary risk are undergoing testing for multiple genes associated with increased cancer risk (Mahon, 2013a). One gene that is commonly included on NGS hereditary breast cancer panels is CHEK2. Increasingly, oncology nurses will encounter patients and families affected with mutations on this gene and need to understand the implications it has for screening and treatment.

Biology of the CHEK2 Gene

The official name of CHEK2 is checkpoint kinase 2 (Shannon & Chitten- den, 2012). The cytogenetic location of CHEK2 is 22q12.1, which means it is located on the long (q) arm of chromosome 22 at position 12.1 from base pair 28,687,742 to base pair 28,741,833. CHEK2 was first linked to breast cancer susceptibility in 2002, and commercial testing is now readily available (Narod, 2010). This gene is passed from generation to generation through autosomal dominant transmission.

The CHEK2 gene provides instructions for making a protein called checkpoint kinase 2, which interacts directly with BRCA1. That protein acts as a tumor suppressor and regulates cell division by keeping cells from growing and dividing too rapidly or in an uncontrolled way. The CHEK2 protein can be activated when either DNA becomes damaged or when breakage of the DNA strands occurs during replication processes when chromosomes exchange genetic material. DNA damage occurs for multiple reasons, including exposure to toxic chemicals, radiation, or ultraviolet light. The CHEK2 gene is activated by the ATM gene, in response to double-stranded breaks (Gage, Wattendorf, & Henry, 2012). CHEK2 is in the middle of a pathway that functions to detect and then determine the cellular response to DNA damage (Tung & Silver, 2011). CHEK2 interacts with several other proteins, including the TP53 gene. Together, the CHEK2, TP53, and other proteins in the pathway halt cell division and determine whether a cell will repair the damage or undergo apoptosis. Ultimately, this process prevents cells with mutated DNA from dividing and forming tumors.

Cancer Risks Associated With CHEK2

Inherited mutations in the CHEK2 gene have been identified in some cases of breast cancer, particularly in European populations. The most commonly seen CHEK2 mutation is associated with the deletion of a single nucleotide at position 1100, known as 1100delC. This is considered a founder mutation and is most commonly found in Caucasian individuals of Northern and Eastern European origin, including descendants of Europeans, such as French Canadians, Jews, and Brazilians (Apostolou & Fostira, 2013; Bodmer & Tomlinson, 2010; Narod, 2010). The 1100delC mutation is known to lead to the production of an abnormally short, nonfunctional version of the CHEK2 protein. Without this protein, cells are unable to regulate cell division properly. The CHEK2 variant 1100delC is estimated to account for about 5% of cases of non-BRCA breast cancer in German populations (Martín et al., 2012). CHEK2 mutations are variable and commonly incomplete (Maxwell & Nathanson, 2013).

Mutations in CHEK2 are considered of medium penetrance and occur with medium frequency for genetic mutations associated with hereditary breast cancer (Gage et al., 2012). CHEK2 mutations are associated with almost a 3-fold increase (25%) in the risk of breast cancer in women and a 10-fold increase in the risk of breast cancer in men (Narod, 2010). The risk is higher when more family members are affected with breast cancer.

For carriers of a mutation in CHEK2, the risk of breast cancer for females with a positive family history of breast cancer is greater than that for a carrier of the same mutation who has no family history of breast cancer (Narod, 2010). Women who are homozygous for this mutation have a significantly higher six-fold risk of developing breast cancer (Lalloo & Evans, 2012). This finding has led to the reasoning that CHEK2 is a modifier of other (possibly unidentified) susceptibility genes for breast cancer. For this reason, during genetic counseling, a relatively higher risk of breast cancer screening and treatment.

Genetics & Genomics
Lisa B. Aiello, RN, MSN, AOCNS®, APN-C • Associate Editor

Vol. 41, No. 6, November 2014 • Oncology Nursing Forum